The urgent need to implement point-of-care RNA testing for hepatitis C virus to support elimination.
hepatitis C
laboratory testing
molecular diagnostics
point-of-care testing
Journal
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213
Informations de publication
Date de publication:
27 Aug 2023
27 Aug 2023
Historique:
received:
30
05
2023
revised:
27
07
2023
accepted:
22
08
2023
medline:
27
8
2023
pubmed:
27
8
2023
entrez:
26
8
2023
Statut:
aheadofprint
Résumé
Hepatitis C virus (HCV) elimination is an important global public health goal. However, the United States (US) is not on track to meet the World Health Organization's 2030 targets for HCV elimination. Recently, the White House proposed an HCV elimination plan that includes point-of-care (POC) HCV RNA testing, which is currently in use in many countries, but is not approved in the US. POC HCV RNA testing is crucial for implementing community-based testing, and for enabling test-and-treat programs, assessing cure, and monitoring for reinfection.. In this commentary, we review the status of POC HCV RNA testing in the US, discuss factors that are needed for successful implementation, and issue specific public health and policy recommendations that would allow for the use of POC HCV RNA testing to support HCV elimination.
Identifiants
pubmed: 37633653
pii: 7252336
doi: 10.1093/cid/ciad503
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.